Drugs / sacubitril/valsartan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06917664 | Jun 2025 → Dec 2026 expected | coronary artery disorder, mitral valve insufficiency | China National Center for Cardiovascular Diseases | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sacubitril/valsartan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06917664 ↗ |
| Action | Inhibit | “angiotensin receptor/neprilysin inhibitor (ARNI)” PMID 40848924 ↗ Aug 2025 |